nach oben

Erschienen in:

05.08.2019 | Review

Platelet–lymphocyte ratio as a potential prognostic factor in gynecologic cancers: a meta-analysis

verfasst von: Shanshan Jiang, Jiandong Liu, Xiangyi Chen, Xinfei Zheng, Junhao Ruan, Aihua Ye, Shufang Zhang, Lingli Zhang, Zhixing Kuang, Rongqiang Liu

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Cancer-related inflammation plays an important role in tumor development and progression. Platelet–lymphocyte ratio (PLR) has been studied as a biomarker for prognosis in gynecologic cancers. But, the results of previous studies were controversial, so we performed this meta-analysis.

Methods

We searched the scientific database of PubMed, Embase, Web of Science, Wanfang, and China National Knowledge Infrastructure (CNKI) using free text and MeSH keywords. Crude HR (hazard ratio) with 95% confidence interval was used to evaluate the risk association between PLR and overall survival (OS) or progression-free survival (PFS) in gynecologic neoplasms.

Results

There totally 23 studies, including 6869 patients who were eligible, most of which are published after 2015 or later. PLR greater than the cut-off was associated with poorer survival prognosis in ovarian cancer [OS: HR 1.80 (95% CI 1.37–2.37), p = 0.000; PFS: HR 1.63 (95% CI 1.38–1.91), p = 0.000] and cervical cancer [OS: HR 1.36 (95% CI 1.10–1.68), p = 0.005; PFS: HR 1.40 (95% CI 1.16–1.70), p = 0.002], but not in endometrial cancer [OS: HR 1.95 (95% CI 0.65–5.84), p = 0.234].

Conclusions

The current meta-analysis revealed that pretreatment PLR was a simple, promising prognostic indicator for OS and PFS in ovarian and cervical cancers. But, its significance of prognosis did not agree with endometrial neoplasm. However, due to the limited number of original studies, future large-scale studies with more well-designed, high-quality studies are still needed.

Candido J, Hagemann T (2013) Cancer-related inflammation. J Clin Immunol 33(Suppl 1):S79–S84CrossRef

Yu X, Lian B, Wang L et al (2014) The pan-cancer analysis of gene expression patterns in the context of inflammation. Mol Biosyst 10:2270–2276CrossRef

Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674CrossRef

Davies C, Pan H, Godwin J et al (2013) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381:805–816CrossRef

DeNardo DG, Coussens LM (2007) Inflammation and breast cancer balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res 9:212CrossRef

Lal I, Dittus K, Holmes CE (2013) Platelets, coagulation and fibrinolysis in breast cancer progression. Breast Cancer Res 15:207CrossRef

Gavalas NG, Karadimou A, Dimopoulos MA, Bamias A (2010) Immune response in ovarian cancer: how is the immune system involved in prognosis and therapy: potential for treatment utilization. Clin Dev Immunol 2010:791603CrossRef

Preston CC, Goode EL, Hartmann LC, Kalli KR, Knutson KL (2011) Immunity and immune suppression in human ovarian cancer. Immunotherapy 3:539–556CrossRef

Del PA, Allavena P, Santoro G et al (2011) Molecular pathways in cancer-related inflammation. Biochem Med (Zagreb) 21:264–275

10.

Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454:436–444CrossRef

11.

Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140:883–899CrossRef

12.

Dreanic J, Dhooge M, Barret M et al (2015) Anti-epidermal or anti-vascular endothelial growth factor as first-line metastatic colorectal cancer in modified Glasgow prognostic score 2’ patients. J Cachexia Sarcopenia Muscle 6:231–236CrossRef

13.

Zhao Y, Adjei AA (2015) Targeting angiogenesis in cancer therapy: moving beyond vascular endothelial growth factor. Oncologist 20:660–673CrossRef

14.

Bambace NM, Holmes CE (2011) The platelet contribution to cancer progression. J Thromb Haemost 9:237–249CrossRef

15.

Acmaz G, Aksoy H, Unal D et al (2014) Are neutrophil/lymphocyte and platelet/lymphocyte ratios associated with endometrial precancerous and cancerous lesions in patients with abnormal uterine bleeding? Asian Pac J Cancer Prev 15:1689–1692CrossRef

16.

Roxburgh CS, McMillan DC (2010) Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol 6:149–163CrossRef

17.

Guthrie GJ, Charles KA, Roxburgh CS et al (2013) The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol 88:218–230CrossRef

18.

Ethier JL, Desautels DN, Templeton AJ et al (2017) Is the neutrophil-to-lymphocyte ratio prognostic of survival outcomes in gynecologic cancers? A systematic review and meta-analysis. Gynecol Oncol 145:584–594CrossRef

19.

Zhao QT, Yuan Z, Zhang H et al (2016) Prognostic role of platelet to lymphocyte ratio in non-small cell lung cancers: a meta-analysis including 3720 patients. Int J Cancer 139:164–170CrossRef

20.

Tan D, Fu Y, Su Q, Wang H (2016) Prognostic role of platelet–lymphocyte ratio in colorectal cancer: a systematic review and meta-analysis. Medicine (Baltimore) 95:e3837CrossRef

21.

Krenn-Pilko S, Langsenlehner U, Thurner EM et al (2014) The elevated preoperative platelet-to-lymphocyte ratio predicts poor prognosis in breast cancer patients. Br J Cancer 110:2524–2530CrossRef

22.

Koh CH, Bhoo-Pathy N, Ng KL et al (2015) Utility of pre-treatment neutrophil-lymphocyte ratio and platelet–lymphocyte ratio as prognostic factors in breast cancer. Br J Cancer 113:150–158CrossRef

23.

Yodying H, Matsuda A, Miyashita M et al (2016) Prognostic significance of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in oncologic outcomes of esophageal cancer: a systematic review and meta-analysis. Ann Surg Oncol 23:646–654CrossRef

24.

Yildirim MA, Seckin KD, Togrul C et al (2014) Roles of neutrophil/lymphocyte and platelet/lymphocyte ratios in the early diagnosis of malignant ovarian masses. Asian Pac J Cancer Prev 15:6881–6885CrossRef

25.

Topcu HO, Guzel AI, Ozer I et al (2014) Comparison of neutrophil/lymphocyte and platelet/lymphocyte ratios for predicting malignant potential of suspicious ovarian masses in gynecology practice. Asian Pac J Cancer Prev 15:6239–6241CrossRef

26.

Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 6:e1000100CrossRef

27.

Parmar MK, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17:2815–2834CrossRef

28.

Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8:16CrossRef

29.

Stang A (2010) Critical evaluation of the Newcastle–Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25:603–605CrossRef

30.

Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558CrossRef

31.

DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188CrossRef

32.

Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719–748PubMed

33.

Onal C, Guler OC, Yildirim BA (2016) Prognostic use of pretreatment hematologic parameters in patients receiving definitive chemoradiotherapy for cervical cancer. Int J Gynecol Cancer 26:1169–1175CrossRef

34.

Zheng RR, Huang M, Jin C et al (2016) Cervical cancer systemic inflammation score: a novel predictor of prognosis. Oncotarget 7:15230–15242PubMedPubMedCentral

35.

Chen L, Zhang F, Sheng XG et al (2016) Peripheral platelet/lymphocyte ratio predicts lymph node metastasis and acts as a superior prognostic factor for cervical cancer when combined with neutrophil: lymphocyte. Medicine (Baltimore) 95:e4381CrossRef

36.

Zhang Y, Wang L, Liu Y et al (2014) Preoperative neutrophil-lymphocyte ratio before Platelet–lymphocyte ratio predicts clinical outcome in patients with cervical cancer treated with initial radical surgery. Int J Gynecol Cancer 24:1319–1325CrossRef

37.

Wang D, Yang JX, Cao DY et al (2013) Preoperative neutrophil-lymphocyte and Platelet–lymphocyte ratios as independent predictors of cervical stromal involvement in surgically treated endometrioid adenocarcinoma. Onco Targets Ther 6:211–216PubMedPubMedCentral

38.

Cummings M, Merone L, Keeble C et al (2015) Preoperative neutrophil: lymphocyte and platelet: lymphocyte ratios predict endometrial cancer survival. Br J Cancer 113:311–320CrossRef

39.

Li J, Lin J, Luo Y, Kuang M, Liu Y (2015) Multivariate analysis of prognostic biomarkers in surgically treated endometrial cancer. PLoS ONE 10:e130640

40.

Miao Y, Yan Q, Li S, Li B, Feng Y (2016) Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are predictive of chemotherapeutic response and prognosis in epithelial ovarian cancer patients treated with platinum-based chemotherapy. Cancer Biomark 17:33–40CrossRef

41.

Raungkaewmanee S, Tangjitgamol S, Manusirivithaya S, Srijaipracharoen S, Thavaramara T (2012) Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer. J Gynecol Oncol 23:265–273CrossRef

42.

Asher V, Lee J, Innamaa A, Bali A (2011) Preoperative platelet–lymphocyte ratio as an independent prognostic marker in ovarian cancer. Clin Transl Oncol 13:499–503CrossRef

43.

Zhang WW, Liu KJ, Hu GL, Liang WJ (2015) Preoperative platelet/lymphocyte ratio is a superior prognostic factor compared to other systemic inflammatory response markers in ovarian cancer patients. Tumour Biol 36:8831–8837CrossRef

44.

Supoken A, Kleebkaow P, Chumworathayi B, Luanratanakorn S, Kietpeerakool C (2014) Elevated preoperative platelet to lymphocyte ratio associated with decreased survival of women with ovarian clear cell carcinoma. Asian Pac J Cancer Prev 15:10831–10836CrossRef

45.

Li Z, Hong N, Robertson M, Wang C, Jiang G (2017) Preoperative red cell distribution width and neutrophil-to-lymphocyte ratio predict survival in patients with epithelial ovarian cancer. Sci Rep 7:43001CrossRef

46.

Wang YQ, Jin C, Zheng HM et al (2016) A novel prognostic inflammation score predicts outcomes in patients with ovarian cancer. Clin Chim Acta 456:163–169CrossRef

47.

Hu D, Lin Y, Liu F et al (2016) Elevated preoperative platelet to lymphocyte ratio indicates poor survival in patients with resected high-grade serous ovarian carcinoma. Clin Lab 62:1443–1449PubMed

48.

Zhou WY, Chen JC, Hui N (2014) Association of pre-treatment platelet-to-lymphocyte ratios with response to neoadjuvant chemotherapy and clinical outcomes of cervical cancer patients. Chin J Clin Oncol 41:1045–1048

49.

Lee JW, Jeon S, Mun ST, Lee SM (2017) Prognostic value of fluorine-18 fluorodeoxyglucose uptake of bone marrow on positron emission tomography/computed tomography for prediction of disease progression in cervical cancer. Int J Gynecol Cancer 27:776–783CrossRef

50.

Haruma T, Nakamura K, Nishida T et al (2015) Pre-treatment neutrophil to lymphocyte ratio is a predictor of prognosis in endometrial cancer. Anticancer Res 35:337–343PubMed

51.

Kozasa K, Mabuchi S, Komura N et al (2017) Comparison of clinical utilities of the platelet count and Platelet–lymphocyte ratio for predicting survival in patients with cervical cancer: a single institutional study and literature review. Oncotarget 8:55394–55404CrossRef

52.

Ceran MU, Tasdemir U, Colak E, Gungor T (2019) Can complete blood count inflammatory parameters in epithelial ovarian cancer contribute to prognosis? A survival analysis. J Ovarian Res 12:16CrossRef

53.

Farolfi A, Petrone M, Scarpi E et al (2018) Inflammatory indexes as prognostic and predictive factors in ovarian cancer treated with chemotherapy alone or together with bevacizumab. A multicenter, retrospective analysis by the MITO Group (MITO 24). Target Oncol 13:469–479CrossRef

54.

Haraga J, Nakamura K, Omichi C et al (2016) Pretreatment prognostic nutritional index is a significant predictor of prognosis in patients with cervical cancer treated with concurrent chemoradiotherapy. Mol Clin Oncol 5:567–574CrossRef

55.

Wang L, Jia J, Lin L et al (2017) Predictive value of hematological markers of systemic inflammation for managing cervical cancer. Oncotarget 8:44824–44832PubMedPubMedCentral

56.

Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357:539–545CrossRef

57.

Zhou X, Du Y, Huang Z et al (2014) Prognostic value of PLR in various cancers: a meta-analysis. PLoS ONE 9:e101119CrossRef

58.

Lippitz BE (2013) Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol 14:e218–e228CrossRef

59.

Klinger MH, Jelkmann W (2002) Role of blood platelets in infection and inflammation. J Interferon Cytokine Res 22:913–922CrossRef

60.

Mantovani A, Romero P, Palucka AK, Marincola FM (2008) Tumour immunity: effector response to tumour and role of the microenvironment. Lancet 371:771–783CrossRef

61.

Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A (2009) Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30:1073–1081CrossRef

62.

Guo L, Liu S, Zhang S et al (2015) C-Reactive protein and risk of breast cancer: a systematic review and meta-analysis. Sci Rep 5:10508CrossRef

63.

Zhou L, Cai X, Liu Q et al (2015) Prognostic role of C-reactive protein in urological cancers: a meta-analysis. Sci Rep 5:12733CrossRef

64.

Bowen RC, Little N, Harmer JR et al (2017) Neutrophil-to-lymphocyte ratio as prognostic indicator in gastrointestinal cancers: a systematic review and meta-analysis. Oncotarget 8:32171–32189CrossRef

65.

Yang JJ, Hu ZG, Shi WX et al (2015) Prognostic significance of neutrophil to lymphocyte ratio in pancreatic cancer: a meta-analysis. World J Gastroenterol 21:2807–2815CrossRef

Titel: Platelet–lymphocyte ratio as a potential prognostic factor in gynecologic cancers: a meta-analysis
verfasst von: Shanshan Jiang
Jiandong Liu
Xiangyi Chen
Xinfei Zheng
Junhao Ruan
Aihua Ye
Shufang Zhang
Lingli Zhang
Zhixing Kuang
Rongqiang Liu
Publikationsdatum: 05.08.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: Archives of Gynecology and Obstetrics / Ausgabe 4/2019
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-019-05257-y

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

Platelet–lymphocyte ratio as a potential prognostic factor in gynecologic cancers: a meta-analysis